Stock comparison
IDEXX Laboratories
MiMedx Group
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
MDXG
MiMedx Group
Market cap
$539.18M
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | MDXG | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 57C | IDXX |
| Benjamin Graham | 80A | 50D | IDXX |
| Philip Fisher | 75B | 54C | IDXX |
| Peter Lynch | 71B | 48D | IDXX |
| Joel Greenblatt | 83C | 22F | IDXX |
| Charlie Munger | 87A | 44D | IDXX |
| Terry Smith | 84A | 51D | IDXX |
Side-by-side metrics
| Metric | IDXX | MDXG |
|---|---|---|
| Market cap | $44.12B | $539.18M |
| P/E (TTM) | 39.0x | 17.6x |
| EV/EBIT | 31.6x | 6.0x |
| ROIC (TTM) | 40.66% | 10.81% |
| Gross margin | 62.05% | 81.04% |
| Net margin | 24.63% | 7.88% |
| Revenue CAGR 5y | 7.56% | 14.68% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$44.12Bvs $539.18M+99%
- ROIC (TTM)40.66%vs 10.81%+73%
- Net margin24.63%vs 7.88%+68%
MDXG leads on
- Debt / Equity0.0xvs 0.7x+99%
- EV/EBIT6.0xvs 31.6x+81%
- P/E (TTM)17.6xvs 39.0x+55%
- Revenue CAGR 5y14.68%vs 7.56%+49%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.